Correlation of glioma cell regression with inhibition of insulin-like growth factor 1 and insulin-like growth factor-binding protein-2 expression

Neuroendocrinology

Volumn 66, Issue 3, 1997, Pages 203-211

  Wang, Zhao Hui ^a   Ma, Junxian ^a   Zeng, Bai Jin ^a   Catanese, Veronica M ^a   Samuels, Stanley ^a   Gama Sosa, Miguel A ^a   Kolodny, Edwin H ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antisense oligonucleotides; Binding proteins; Glioma; Insulin like growth factors; Molecular neuroendocrinology

Indexed keywords

COMPLEMENTARY RNA; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN C;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CULTURE; CELL GROWTH; CONTROLLED STUDY; CULTURE MEDIUM; DNA SYNTHESIS; GLIA CELL; GLIOMA CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; CELL DIVISION; CELL LINE, TRANSFORMED; CELL SURVIVAL; CULTURE MEDIA, CONDITIONED; DNA, NEOPLASM; GENETIC VECTORS; GLIOMA; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INSULIN-LIKE GROWTH FACTOR I; PHENOTYPE; RATS; RATS, SPRAGUE-DAWLEY; RETROVIRIDAE; RNA, ANTISENSE; TUMOR CELLS, CULTURED;

EID: 0030740038     PISSN: 00283835     EISSN: 14230194     Source Type: Journal    
DOI: 10.1159/000127239     Document Type: Article

References (30)

1. Karp JH, Broder S: New directions in molecular medicine. Cancer Res 1994;54:653-665.
2. Trojan J, Blossey BK, Johnson TR, Rudin SD, Tykocinski M, Ilan J, Ilan J: Loss of tumorige-nicity of rat glioblastoma directed by cpisomc-based antisense cDNA transcription of insulinlike growth factor I. Proc Natl Acad Sci USA 1992;89:4874-4878.
3. Takamiva Y, Short MP, Moolten FL, Fleet C, Mincta T, Breakefield XO, Martuza RL: An experimental model of retrovirus gene therapy for malignant brain tumors. J Neurosurg 1993; 79:104-110.
4. Boviatsis EJ, Chase M, Wei MX, Tamiya T, Hurford RK Jr, Kowall NW, Tepper RI, Breakefield XO, Chiocca EA: Gene transfer into experimental brain tumors mediated by adenovirus, herpes simplex virus, and retrovirus vectors. Hum. Gene Ther 1994;5:183-191.
5. Trojan J, Johnson TR, Rudin SD, Ilan J, Tykocinski ML, Ilan J: Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor 1 RNA. Science 1993:259:94-97.
6. Rcsnicoff M, Sell C, Rubini M, Coppola D, Ambrose D, Baserga R, Rubin R: Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-I (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors. Cancer Res 1994:54:2218-2222.
7. Rcsnicoff M, Coppola D, Sell C, Rubini R, Ferrone S, Baserga R: Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type I insulin-like growth factor receptor. Cancer Res 1994:54:4848-4850.
8. Prager D, Li HL, Asa S, Melmed S: Dominant ncgalive inhibition of tumorigcnesis in vivo by human insulin-like growth factor I receptor mutant. Proc Natl Acad Sci USA 1994:91: 2181-2185.
9. Jones JI. Clemmons DR: Insulin-like growth factors and their binding proteins: biological actions. EndocrRcv 1995:16:3-34.
10. Valentinis B, Bhala A, DeAngelis T, Baserga R, Cohen P: The human insulin-like growth factor (IGF) binding protein-3 inhibits the growth of fibroblasts with a targeted disruption of the IGF-1 receptor gene. Mol Endocrinol 1995:9: 361-367.
11. Vincent TS, Garvin J, Gramling TS, Hazen-Martin D, Re GG. Sens DA: Expression of insulin-like growth factor binding protein 2 (IGFBP-2) in Wilms tumors. Pediatr Pathol 1994:14:723-730.
12. Muller HE, Oh Y. Lehrnbecher T, Blum WF, Rosenfeld RG: Insulin-like growth factor-binding protcin-2 concentrations in cerebrospinal fluid and serum of children with malignant solid tumors or acute leukemia. J Clin Endocrinol Metab 1994;79:428-434.
13. Cohen P, Pcehl DM, Stamcy TA, Wilson KF, Clemmons DR, Rosenfeld RG: Elevated levels of insulin-like growth factor-binding prolein-2 in the scrum of prostate cancer patients. J Clin Endocrinol Metab 1993;76:1031-1035.
14. Reeve JG, Kirby LB, Brinkman A: Insulin-like growth factor-binding prolcin gene expression and protein production by human tumor cell lines. Int J Cancer 1992;51:818-821.
15. Adamo ML, Shao ZM, Lannau F, Chen JC, Clemmons DR, Roberts CT, Leroith D, Fontana JA: Insulin-like growth factor-I (IGF-1) and retinoic acid modulation of IGF-binding proteins (IGFBPs): IGFBP-2, -3, and -4 gene expression and protein secretion in a breast cancer cell line. Endocrinology 1992; 131:1858-1866.
16. Reeve JG, Morgan J, Sclnvander J, Bleehen NM: Role for membrane and secreted insulinlike growth factor-binding protein-2 in the regulation of insulin-like growth factor action in lung tumors. Cancer Res 1993:53:4680-4685.
17. Cole R, de Vellis J: Preparation of astrocyte and oligodendrocyte cultures from rat glial cultures; in Shahar A. de Vellis J, Vemadakis A, Haber BS (eds): A Dissection and Tissue Culture Manual of the Nervous System. New York. Liss, 1989. pp 121-133.
18. McCarthy KD, de Vellis J: Preparation of separate astroglial and oligodendroglia cell cultures from rat cerebral tissue. J Cell Biol 1980:85: 890-902.
19. Miller AD, Rosman GJ: Improved retroviral vectors for gene transfer and expression. Bio-techniques 1989;7:980-990.
20. Maniatis T, Fritsch EF, Satnbrook J: Molecular Clonning: A Laboratory Manual, ed 2. Cold Spring Harbor, Cold Spring Harbor Laboratory, 1989.
21. Harris JD, Gutierrez AA, Hurst HC, Sikora K, Lemoine NR: Gene therapy for cancer using tumor-specific prodrug activation. Gene Ther 1994;1:170-175.
22. Lowe WL Jr, Meyer T, Karpen CW, Lorentzen LR: Regulation of insulin-like growth factor I production in rat C6 glioma cells: Possible role as an autocrine/paracrine growth factor. Endocrinology 1992:130:2683-2691.
23. Sell C, Rubini M, Rubin R, Liu J.-P, Efstratia-dis A, Baserga R: Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci USA 1993;90:11217-11221.
24. Kaleko M, Rutter WJ, and Miller AD: Overexpression of the human insulin-like growth factor 1 receptor promotes ligand-dependent neoplastic transformation. Mol Cell Biol 1990:10: 464-473.
25. Pass HI, Mew DJY, Carbone M, Matthews WA, Donington JS. Baserga R, Walker CL, Resnicoff M, Steinberg SM: Inhibition of hamster mesothelioma tumorigenesis by an anti-sense expression plasmid to the insulin-like growth factor-1 receptor. Cancer Res 1996,56: 4044-4048.
26. Coppola D, Ferber A, Miura M, Sell C, Dambrosio C, Rubin R, Baserga R: A functional insulin-like growth factor 1 receptor is required for the ntitogenic and transforming activities of the epidermal growth factor receptor. Mol Cell Biol 1994;14:4588-4595.
27. Kiess W, Lee L, Graham DE, Greenstein L, Tseng LYH, Rechler MM, Nissley SP: Rat C6 glial cells synthesize insulin-like growth factor 1 (IGF-I) and express IGF-1 receptors and 1GF-II/mannose 6-phosphatc receptors. Endocrinology 1989:124:1727-1736.
28. Antoniades HN, Galanopoulos T, Neville-Golden J, Maxwell M: Expression of insulin-like growth factors I and II and their receptor mRNAs in primary human astrocytomas and meningiomas: In vivo studies using in situ hybridization and immunocytochcmistry. Int J Cancer 1992;50:215-222.
29. Johnson TR, Trojan J, Rudin SD, Ban J, Tykocinski ML, Ilan J: Evoking an immune response to glioblastoma cells transfected with episomc-based plasmid expressing antisensc transcripts to insulin-like growth factor I; in Levine AJ, Schmidek HH (eds): Molecular Genetics of Nervous System Tumors. New York. Wilev-Liss, 1993. pp 387-400.
30. Boumer MJ, Busby WH, Siegel NR, Krivi GG, McCusker RH, Clemmons DR: Cloning and sequence determination of bovine insulin-like growlh factor binding protein-2 (IGFBP-2): Comparison of its structural and functional properties with IGFBP-1. J Cell Biochcm 1992: 48:215-226.